Skip to content

Vital Signs: Future of Healthcare

Our round-up of the year in biotech for JPM Week 2025. Produced by Onyx and published by Fortune.

Healthy human cells of connective tissue, observed in culture. Magnification 500x. Photo by National Cancer Institute

Table of Contents

Editor's note

Vital Signs was published in Fortune magazine on December 1, 2024, and was a feature length project produced by Onyx Newsroom to share key healthcare voices with the world ahead of JPM Week 2025.

There is a lot to achieve in healthcare in 2025, and a lot of change on the horizon. We'll be reporting live. You can sign up to my newsletter below.

- Dr. Adil Ali, Editor-in-Chief


Intro

The Westin St. Francis in San Francisco has endured earthquakes, pampered presidents, and even facilitated early meetings of the United Nations in 1945. And for the last 42 years, this grand old hotel has hosted an annual event of truly global significance. The J.P. Morgan Healthcare Conference, colloquially known as JPM Week, is where big bucks and big pharma meet ambitious biotech CEOs.

Many in the industry see it as a State of the Union for healthcare—and the time to make big bets on winners and losers for the year ahead. In 2024, GLP-1 agonists dominated the conversation. In 2025, what will be the next big thing in healthcare? Ahead of JPM Week 2025 (Jan. 13–16), the Onyx Newsroom team interviewed CEOs from around the world...

🔍
Click + icon on the right panel to zoom in. You can also download your free PDF copy of Vital Signs here.
0:00
/0:14

Fortune Dec 2024/Jan 2025 Edition